• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Association of the serotonin transporter-linked polymorphic region genotype with lower bone mineral density.血清素转运体相关多态区基因型与较低的骨密度有关。
Transl Psychiatry. 2017 Aug 22;7(8):e1213. doi: 10.1038/tp.2017.184.
2
Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics.血清素转运体基因变体、选择性 5-羟色胺再摄取抑制剂与利培酮治疗男孩的骨密度:一项基于药物遗传学的重点为横断面研究数据的再分析。
J Clin Psychiatry. 2011 Dec;72(12):1685-90. doi: 10.4088/JCP.10m06198.
3
Use of selective serotonin reuptake inhibitors and bone mass in adolescents: An NHANES study.青少年中选择性5-羟色胺再摄取抑制剂的使用与骨量:一项美国国家健康和营养检查调查研究
Bone. 2015 Sep;78:28-33. doi: 10.1016/j.bone.2015.04.042. Epub 2015 May 2.
4
The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients.5-羟色胺转运蛋白基因(5-HTTLPR)和STin2多态性对抑郁症患者选择性5-羟色胺再摄取抑制剂治疗效果的影响。
Psychiatr Genet. 2008 Aug;18(4):184-90. doi: 10.1097/YPG.0b013e3283050aca.
5
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.成年重度抑郁症门诊患者中功能性5-羟色胺转运体启动子多态性与西酞普兰治疗的关联。
Arch Gen Psychiatry. 2007 Jul;64(7):783-92. doi: 10.1001/archpsyc.64.7.783.
6
Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.5-羟色胺转运体基因多态性与艾司西酞普兰治疗韩国抑郁症患者的疗效相关性。
Neuropsychobiology. 2012;66(4):221-9. doi: 10.1159/000341876. Epub 2012 Oct 20.
7
The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study.5-羟色胺转运体基因连锁多态性区域(5-HTTLPR)对艾司西酞普兰急性阻断5-羟色胺转运体后情绪加工的影响:一项随机交叉功能磁共振成像研究的初步结果
Aust N Z J Psychiatry. 2014 Dec;48(12):1115-25. doi: 10.1177/0004867414533837. Epub 2014 May 8.
8
Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis.选择性 5-羟色胺再摄取抑制剂对骨密度的影响:系统评价和荟萃分析。
Osteoporos Int. 2018 Jun;29(6):1243-1251. doi: 10.1007/s00198-018-4413-0. Epub 2018 Feb 12.
9
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.老年男性低骨密度与使用选择性5-羟色胺再摄取抑制剂的关联
Arch Intern Med. 2007 Jun 25;167(12):1246-51. doi: 10.1001/archinte.167.12.1246.
10
Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.血清素转运体基因位点在老年期重度抑郁症患者对选择性5-羟色胺再摄取抑制剂治疗反应中的作用。
J Psychopharmacol. 2015 May;29(5):623-33. doi: 10.1177/0269881115578159. Epub 2015 Mar 31.

引用本文的文献

1
The Impact of Psychotropic Medications on Bone Health in Youth.精神类药物对青少年骨骼健康的影响。
Curr Psychiatry Rep. 2018 Sep 24;20(11):104. doi: 10.1007/s11920-018-0960-5.

本文引用的文献

1
Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect.血清素再摄取抑制剂通过抵消局部抗吸收作用在小鼠体内产生中枢性骨质流失。
Nat Med. 2016 Oct;22(10):1170-1179. doi: 10.1038/nm.4166. Epub 2016 Sep 5.
2
Increased risk of osteoporosis in patients with depression: a population-based retrospective cohort study.抑郁症患者骨质疏松症风险增加:基于人群的回顾性队列研究。
Mayo Clin Proc. 2015 Jan;90(1):63-70. doi: 10.1016/j.mayocp.2014.11.009.
3
Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States.美国绝经后妇女骨质疏松性骨折与其他严重疾病的疾病负担比较。
Mayo Clin Proc. 2015 Jan;90(1):53-62. doi: 10.1016/j.mayocp.2014.09.011. Epub 2014 Dec 4.
4
Depression, antidepressants, and bone health in older adults: a systematic review.老年人的抑郁症、抗抑郁药与骨骼健康:一项系统综述
J Am Geriatr Soc. 2014 Aug;62(8):1434-41. doi: 10.1111/jgs.12945. Epub 2014 Jul 15.
5
Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010.按国家、性别、年龄和年份划分的抑郁障碍负担:来自 2010 年全球疾病负担研究的发现。
PLoS Med. 2013 Nov;10(11):e1001547. doi: 10.1371/journal.pmed.1001547. Epub 2013 Nov 5.
6
Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.血清素转运体和5-羟色胺受体1B(HTR1B)受体的基因变异预示着老年人在服用血清素再摄取抑制剂治疗期间骨形成减少。
World J Biol Psychiatry. 2014 Jul;15(5):404-10. doi: 10.3109/15622975.2013.832380. Epub 2013 Sep 30.
7
Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics.血清素转运体基因变体、选择性 5-羟色胺再摄取抑制剂与利培酮治疗男孩的骨密度:一项基于药物遗传学的重点为横断面研究数据的再分析。
J Clin Psychiatry. 2011 Dec;72(12):1685-90. doi: 10.4088/JCP.10m06198.
8
Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis.靶向 DKK1、LRP5 和血清素的治疗方法在骨质疏松症治疗中的潜在作用。
Curr Osteoporos Rep. 2012 Mar;10(1):93-100. doi: 10.1007/s11914-011-0086-8.
9
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.基于 5-羟色胺转运体基因启动子多态性(5-HTTLPR)与抗抑郁疗效关联的荟萃分析
Eur Neuropsychopharmacol. 2012 Apr;22(4):239-58. doi: 10.1016/j.euroneuro.2011.10.003. Epub 2011 Dec 3.
10
Association of serotonin transporter gene polymorphism 5HTTVNTR with osteoporosis.
Acta Reumatol Port. 2011 Jan-Mar;36(1):14-9.

血清素转运体相关多态区基因型与较低的骨密度有关。

Association of the serotonin transporter-linked polymorphic region genotype with lower bone mineral density.

机构信息

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.

出版信息

Transl Psychiatry. 2017 Aug 22;7(8):e1213. doi: 10.1038/tp.2017.184.

DOI:10.1038/tp.2017.184
PMID:28892067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5611748/
Abstract

The serotonin transporter-linked polymorphic region (5-HTTLPR) of the serotonin transporter gene (SLC6A4) S allele is linked to pathogenesis of depression and slower response to selective serotonin reuptake inhibitors (SSRIs); depression and SSRIs are independently associated with bone loss. We aimed to determine whether 5-HTTLPR was associated with bone loss. This cross-sectional study included psychiatric patients with both 5-HTTLPR analysis and bone mineral density (BMD) assessment (hip and spine Z-scores if age <50 years and T-scores if ⩾50 years). BMD association with 5-HTTLPR was evaluated under models with additive allele effects and dominant S allele effects using linear regression models. Patients were stratified by age (<50 and ⩾50 years) and sex. Of 3016 patients with 5-HTTLPR genotyping, 239 had BMD assessments. Among the younger patients, the S allele was associated with lower Z-scores at the hip (P=0.002, dominant S allele effects; P=0.004, additive allele effects) and spine (P=0.0006, dominant S allele effects; P=0.01, additive allele effects). In sex-stratified analyses, the association of the S allele with lower BMD in the younger patients was also significant in the subset of women (P⩽0.003 for both hip and spine BMD under the additive allele effect model). In the small group of men younger than 50 years, the S allele was marginally associated with higher spine BMD (P=0.05). BMD T-scores were not associated with 5-HTTLPR genotypes in patients 50 years or older. The 5-HTTLPR variants may modify serotonin effects on bone with sex-specific effects.

摘要

5-羟色胺转运体基因(SLC6A4)的 5-羟色胺转运体连接多态区(5-HTTLPR)的 S 等位基因与抑郁症的发病机制和对选择性 5-羟色胺再摄取抑制剂(SSRIs)的反应较慢有关;抑郁症和 SSRIs 均与骨量流失独立相关。我们旨在确定 5-HTTLPR 是否与骨量流失有关。这项横断面研究包括同时进行了 5-HTTLPR 分析和骨密度(BMD)评估的精神科患者(年龄<50 岁时为髋部和脊柱 Z 评分,年龄 ⩾50 岁时为 T 评分)。使用线性回归模型,根据加性等位基因效应和显性 S 等位基因效应的模型评估 BMD 与 5-HTTLPR 的相关性。根据年龄(<50 岁和 ⩾50 岁)和性别对患者进行分层。在 3016 名接受 5-HTTLPR 基因分型的患者中,有 239 名进行了 BMD 评估。在年轻患者中,S 等位基因与髋部(P=0.002,显性 S 等位基因效应;P=0.004,加性等位基因效应)和脊柱(P=0.0006,显性 S 等位基因效应;P=0.01,加性等位基因效应)Z 评分较低相关。在按性别分层的分析中,在女性亚组中,S 等位基因与年轻患者较低的 BMD 之间的关联也具有统计学意义(加性等位基因效应模型下,髋部和脊柱 BMD 均为 P ⩽0.003)。在年龄小于 50 岁的男性小群体中,S 等位基因与脊柱 BMD 升高有一定的关联(P=0.05)。50 岁及以上患者的 BMD T 评分与 5-HTTLPR 基因型无关。5-HTTLPR 变体可能通过性别特异性效应来调节 5-羟色胺对骨骼的作用。